Related Experiment Video

Updated: Jun 23, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Clinical insights from the Treating to New Targets trial

David D Waters1

  • 1Division of Cardiology, San Francisco General Hospital, University of California, San Francisco, CA, USA. dwaters@medsfgh.ucsf.edu

Progress in Cardiovascular Diseases
|May 5, 2009
PubMed

Insights

Higher dose atorvastatin (80 mg) significantly reduced cardiovascular events in patients with coronary disease compared to a lower dose (10 mg). This intensive statin therapy proved safe and cost-effective, especially for high-risk subgroups.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Coronary artery disease (CAD) management often involves statin therapy to lower low-density lipoprotein cholesterol (LDL-C).
  • The optimal dosage of atorvastatin for maximizing cardiovascular event reduction in patients with stable CAD remains an area of investigation.

Purpose of the Study:

  • To compare the efficacy and safety of high-dose (80 mg) versus standard-dose (10 mg) atorvastatin in patients with coronary disease.
  • To evaluate the impact of intensive LDL-C lowering on cardiovascular outcomes in diverse patient subgroups.

Main Methods:

  • The Treating to New Targets (TNT) trial randomized 10,001 patients with coronary disease to receive either atorvastatin 80 mg/day or 10 mg/day.
  • Patients were followed for a median of 4.9 years, with cardiovascular events and safety data meticulously recorded.

Main Results:

  • High-dose atorvastatin (80 mg) significantly reduced the primary composite endpoint (cardiovascular death, myocardial infarction, cardiac arrest, stroke) by 15% compared to the 10-mg dose (8.7% vs 10.9%, P = .0002).
  • Absolute risk reduction was greater in subgroups with diabetes, metabolic syndrome, chronic kidney disease, or prior coronary artery bypass grafting (CABG).
  • Stroke and heart failure hospitalization rates were significantly lower with 80 mg atorvastatin; the safety profile was excellent.

Conclusions:

  • High-dose atorvastatin (80 mg) provides incremental cardiovascular benefits over standard-dose (10 mg) in patients with stable coronary disease.
  • The 80-mg dose is safe, cost-effective, and particularly beneficial for high-risk patient populations.
  • Wider adoption of high-dose atorvastatin is recommended for improved patient outcomes.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...